Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation
| Status: | Withdrawn |
|---|---|
| Conditions: | Skin and Soft Tissue Infections, Dermatology |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/3/2018 |
| Start Date: | February 2016 |
| End Date: | December 2019 |
The proposed research is intended to determine if supplementation of relatively high dose
vitamin D in chronic urticaria patients receiving omalizumab will result in continued
symptomatic control of hives after the discontinuation of omalizumab.
vitamin D in chronic urticaria patients receiving omalizumab will result in continued
symptomatic control of hives after the discontinuation of omalizumab.
Inclusion Criteria:
- Physician diagnosed chronic urticaria
- Currently be receiving omalizumab therapy for the treatment of chronic idiopathic
urticaria and be well controlled with a USS <25
Exclusion Criteria:
- Not capable of informed consent.
- Not capable of answering the questionnaire.
- Subjects with a pure physical urticaria.
- Pregnant or lactating women.
- Subjects with hypercalcemia (calcium > 10.3 mg/dl) or renal insufficiency (GFR <50
ml/min).
- Subjects with prior anaphylaxis to omalizumab.
- Currently taking high dose vitamin D supplementation.
- Prior high dose vitamin D supplementation for urticaria with failure.
- Baseline 25(OH)D >80 ng/ml
- Subjects with sarcoidosis, hyperparathyroidism, histoplasmosis, lymphoma or
tuberculosis
We found this trial at
1
site
University of Kansas Medical Center The University of Kansas Medical Center serves Kansas through excellence...
Click here to add this to my saved trials
